The
View from Here
Michael J. Curtis
Safety Pharmacology is presently an orphan discipline that occupies
a space between science and regulation. As a science, it is subject
to the laws of the scientific method (hypothesis testing)...
Read
more...
Upcoming Issues
Issue 2/February '07
Pharmaco-
economics
Issue 3/March '07
Chemoinformatics
Issue 4/April '07
Nanotechnology
|
A
review of 2006
|
| |
Top
Reviews |
 |
In
vitro safety pharmacology profiling: an essential tool for
successful drug development
Whitebread
S, Hamon J, Bojanic D, Urban L.
Drug Discovery Today
2005; 10(21):1421-33.
Broad-scale
in vitro pharmacology profiling of new chemical entities
during early phases of drug discovery has recently become an essential
tool to predict clinical adverse effects...
|
| |
In
silico prediction of drug safety: despite progress there is
abundant room for improvement
Egan, WJ, Zlokarnik, G, Grootenhuis, PDJ
Drug Discovery Today: Technologies 2004; 1(4): 381-387.
Predictive
models for drug safety are crucial for helping to avoid costly late-stage
failures. We review recent work on models for genotoxicity, liver
toxicity, CYP450 inhibition and cardiotoxicity...
|
| |
Why
optimize cancer drugs for ADMET?
Sheppard, GS, Bouska. JJ
Drug Discovery Today: Therapeutic Strategies
2005; 2(4): 343-349.
In
an effort to avoid clinical failures, there is an emphasis across
the pharmaceutical industry on examining pharmacokinetic and safety
profiles earlier in the drug discovery process. Although oncology
is more forgiving of delivery and side effect compromises than most
therapeutic areas, cancer discovery programs are not immune from
this trend...
|
|
| |
Abstracts
of Key Research Articles
International
Conference on Harmonisation; guidance on S7B Nonclinical Evaluation
of the Potential for Delayed Ventricular Repolarization (QT Interval
Prolongation) by Human Pharmaceuticals; availability
Food and Drug Administration, HHS.
Fed Regist. 2005; 70(202):61133-45.
ICH
S7B draft guideline on the non-clinical strategy for testing delayed
cardiac repolarisation risk of drugs: a critical analysis
Cavero, I, Crumb, W
Expert Opin Drug Saf. 2005; 4(3):509-30.
Assessment
of renal injury in vivo
Emeigh Hart, SG
J. Pharmacol Toxicol Methods 2005; 52(1):30-45
Methods
for screening drugs for their pro-arrhythmic liability: does the
rabbit ventricular wedge hold the key?
Hancox, JC, Curtis, MJ
J. Pharmacol Toxicol Methods 2006; 54(3):257-60.
ILSI-HESI
cardiovascular safety subcommittee initiative: evaluation of three
non-clinical models of QT prolongation
Hanson, LA, Bass, AS, Gintant, G, Mittelstadt, S, Rampe, D, Thomas,
K
J Pharmacol Toxicol Methods 2006; 54(2):116-29.
Validation
of a motor activity system by a robotically controlled vehicle
and using standard reference compounds
Patterson, JP, Markgraf, CG, Cirino, M, Bass, AS
J Pharmacol Toxicol Methods 2005; 52(1):159-67.
Effect
of commonly used vehicles on gastrointestinal, renal, and liver
function in rats
Pestel, S, Martin, HJ, Maier, GM, Guth, B
J Pharmacol Toxicol Methods 2006; 54(2):200-14.
Assessing
the proarrhythmic potential of drugs: current status of models
and surrogate parameters of torsades de pointes arrhythmias
Thomsen, MB, Matz, J, Volders, PG, Vos, MA
Pharmacol Ther. 2006; 112(1):150-70.
HERG-Lite:
a novel comprehensive high-throughput screen for drug-induced
hERG risk
Wible, BA, Hawryluk, P, Ficker, E, Kuryshev, YA, Kirsch, G, Brown,
AM
J Pharmacol Toxicol Methods 2005; 52(1):136-45.
|
|
